Alzamend Neuro, Inc.
ALZNNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$4.5M | −$9.9M | −$14.9M | −$12.3M | −$5.0M | −$4.4M |
| Net income | −$4.5M | −$9.9M | −$14.9M | −$12.4M | −$5.0M | −$4.4M |
| Total assets | $4.6M | $631,588 | $5.9M | $14.5M | $2.9M | $1.8M |
| Total liabilities | $634,761 | $3.2M | $2.9M | $1.2M | $899,643 | — |
| Equity | $4.0M | −$2.6M | $3.0M | $13.4M | $2.0M | $821,709 |
| EPS (diluted) | $-11.32 | $-132.33 | $-22.89 | $-0.14 | — | — |
| Shares out. | 2.9M | 841,240 | 96.9M | 95.5M | 85.3M | 64.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −113.8%
- Return on assets
- −98.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 13.8%
- Debt / equity
- 0.16×
- Book value / share
- $1.37
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 44.6%high accruals
- Piotroski F-Score
- 2/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 1 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jul 30, 2024
- NT 10-Qmissed a reporting deadline ↗Mar 18, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2025-12A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
- Phase 1/2Recruitingreadout ~2026-12A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
- Phase 1/2Active Not Recruitingreadout ~2028-03-03Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ault Milton C IiiActivist (13D)Oct 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ault Milton C IiiDirector | Apr 14, 2026 | Buy | 108,388 | $1.00 |
| Ault Milton C IiiDirector | Dec 23, 2025 | Sell | 1,851 | $2.07 |
| Horne William B.Director | Dec 19, 2025 | Sell | 3,333 | $2.12 |
| Mcgrath Lynne FaheyDirector | Oct 23, 2025 | Sell | 30 | $2.29 |
| Ault Milton C IiiDirector | Oct 8, 2025 | Conversion | 61,743 | $2.32 |
| Ault Milton C IiiDirector | Oct 3, 2025 | Conversion | 100,000 | $2.32 |
| Ault Milton C IiiDirector | Oct 1, 2025 | Conversion | 100,000 | $2.32 |
| Ault Milton C IiiDirector | Sep 26, 2025 | Sell | 37,738 | $2.31 |
| Ault Milton C IiiDirector | Sep 23, 2025 | Sell | 43,238 | $2.38 |
| Ault Milton C IiiDirector | Sep 19, 2025 | Sell | 77,009 | $2.35 |
| Ault Milton C IiiDirector | Sep 17, 2025 | Conversion | 100,000 | $2.32 |
| Ault Milton C IiiDirector | Jul 30, 2025 | Conversion | 100,000 | $2.32 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 199,574 | 5.3 | -2.5% |
| Apr 30, 2026 | 204,743 | 3.5 | -17.6% |
| Apr 15, 2026 | 248,546 | 2.5 | -23.8% |
| Mar 31, 2026 | 326,187 | 1.0 | +32.6% |
| Mar 13, 2026 | 246,072 | 4.7 | -8.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteApr 17, 2026
- Delisting / listing-standard noticeMar 20, 2026
- Entered a material agreementMar 6, 2026
- Other material eventNov 18, 2025
- Amended charter or bylawsOct 14, 2025
- Unregistered equity saleOct 9, 2025
- Unregistered equity saleSep 25, 2025
- Unregistered equity saleAug 1, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KApr 17, 2026
- 4PRIMARY DOCUMENTApr 16, 2026
- 8-KMar 20, 2026
- 10-QMar 11, 2026
- 424B5Mar 6, 2026
- 8-KMar 6, 2026
- DEFA14AFeb 26, 2026
- DEF 14AFeb 26, 2026
- PRE 14AFeb 9, 2026
- 4PRIMARY DOCUMENTDec 30, 2025
- 4PRIMARY DOCUMENTDec 23, 2025
- 10-QDec 9, 2025
- 8-KNov 18, 2025
- 4PRIMARY DOCUMENTOct 24, 2025
- 8-KOct 14, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.